isoproterenol and 2,5-dimethylcelecoxib

isoproterenol has been researched along with 2,5-dimethylcelecoxib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arioka, M; Igawa, K; Ishikane, S; Kuroo, A; Morishige, S; Sasaguri, T; Shiose, A; Takahashi-Yanaga, F; Tomooka, K	1

Other Studies

1 other study(ies) available for isoproterenol and 2,5-dimethylcelecoxib

Article	Year
2,5-Dimethylcelecoxib prevents isoprenaline-induced cardiomyocyte hypertrophy and cardiac fibroblast activation by inhibiting Akt-mediated GSK-3 phosphorylation. Biochemical pharmacology, 2019, Volume: 168 Topics: Animals; Animals, Newborn; Cardiomegaly; Disease Models, Animal; Fibroblasts; Glycogen Synthase Kinase 3; Isoproterenol; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Ventricular Remodeling	2019

Article

Year

2,5-Dimethylcelecoxib prevents isoprenaline-induced cardiomyocyte hypertrophy and cardiac fibroblast activation by inhibiting Akt-mediated GSK-3 phosphorylation.

Biochemical pharmacology, 2019, Volume: 168

Topics: Animals; Animals, Newborn; Cardiomegaly; Disease Models, Animal; Fibroblasts; Glycogen Synthase Kinase 3; Isoproterenol; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Ventricular Remodeling

2019